Success Metrics

Clinical Success Rate
75.0%

Based on 6 completed trials

Completion Rate
75%(6/8)
Active Trials
0(0%)
Results Posted
83%(5 trials)
Terminated
2(22%)

Phase Distribution

Ph phase_2
2
22%
Ph phase_1
7
78%

Phase Distribution

7

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
7(77.8%)
Phase 2Efficacy & side effects
2(22.2%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(6)
Terminated(2)
Other(1)

Detailed Status

Completed6
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Phase 17 (77.8%)
Phase 22 (22.2%)

Trials by Status

unknown111%
terminated222%
completed667%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_1

p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

NCT02098343
completedphase_2

p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246

NCT03268382
completedphase_2

APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant

NCT03931291
completedphase_1

APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

NCT04214860
completedphase_1

Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms

NCT03072043
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT02098343Phase 1

p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

Completed
NCT03268382Phase 2

p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246

Completed
NCT03931291Phase 2

APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant

Completed
NCT04214860Phase 1

APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

Completed
NCT03072043Phase 1

Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms

Completed
NCT02999893Phase 1

A Study of APR-246 in Oesophageal Cancer

Terminated
NCT03588078Phase 1

Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine

Unknown
NCT00900614Phase 1

Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer

Completed
NCT03391050Phase 1

A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma

Terminated

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9